Jean-Paul Clozel Net Worth: Estimated Range and How It’s Calculated

Based on publicly disclosed shareholdings and Idorsia's market capitalization as of early 2026, Jean-Paul Clozel's net worth is most credibly estimated in the range of CHF 150 million to CHF 400 million, with the actual figure highly sensitive to Idorsia's share price on any given day. The wide range reflects real uncertainty: his wealth is concentrated in equity of a mid-cap Swiss biotech that has faced significant financial turbulence, making a single precise number misleading rather than helpful.

Who Jean-Paul Clozel is and why people look him up

Jean-Paul Clozel is a French-born physician-scientist who co-founded Actelion, Switzerland's most successful homegrown biotech company, alongside his wife Martine Clozel and other partners. He trained in medicine in France, then at the University of Montreal and UCSF, before channeling that background into drug development. Actelion became a European biotech landmark, and when Johnson & Johnson acquired it in a deal completed on June 16, 2017 for approximately $30 billion in cash (at $280 per share), the Clozels did not simply cash out and walk away. They negotiated to spin out Actelion's research pipeline into a new Swiss company called Idorsia, which Jean-Paul led as CEO for nearly 27 years total across both companies. He later transitioned to Chairman and has served as interim CEO during leadership transitions. That combination of a $30 billion exit and a continued, significant equity stake in a publicly traded successor company is exactly why his name comes up in wealth research.

People specifically search for his net worth because the Actelion deal was one of the largest European biotech acquisitions in history, and it's reasonable to assume the founders captured substantial value. However, how much of that value Clozel personally realized, and how much remains tied up in Idorsia's equity, is the crux of the question.

What 'net worth' actually means here

Net worth is total assets minus total liabilities. For a public figure with a significant stake in a listed company, the dominant asset is usually that equity stake, valued at the current market price. That sounds straightforward, but there are real complications. First, Jean-Paul Clozel's wealth is not fully public. Switzerland does not require personal wealth declarations, and he is not subject to the kind of disclosure requirements that apply to, say, U.S. billionaires filing SEC beneficial ownership reports. What is public are the major shareholder disclosures that Swiss listed companies must file when insiders cross ownership thresholds (3%, 5%, 10%, and so on, per the Financial Market Infrastructure Act and SIX Exchange rules), plus what Idorsia voluntarily publishes in its annual reports. Second, a large block of shares in a thinly traded biotech is not the same as cash. Even if the math says his stake is worth CHF 300 million at today's price, selling that much equity without moving the market is a different story. Third, his wealth includes instruments beyond ordinary shares, such as conversion rights from convertible bonds, which add upside but also complexity. Any figure you see online that doesn't acknowledge these layers should be treated with skepticism.

The best available public signals on his net worth

There are two main evidentiary pillars: what the Clozels received from the Actelion sale, and what they currently hold in Idorsia.

The Actelion windfall

Reuters reporting citing Actelion's 2015 annual report puts Jean-Paul and Martine Clozel's combined ownership at approximately 5.03% of Actelion shares at that time. At a $30 billion total deal value, 5% translates to roughly $1.5 billion in gross proceeds before tax, brokerage, and any other transaction costs. This is not a verified personal cash figure, it is a rough upper bound on the cash component of their Actelion exit. Swiss capital gains tax on shares held long-term by private individuals is generally zero under Swiss law (though French tax residency considerations may apply differently), which is relevant context. Even so, a significant portion of that value was almost certainly reinvested rather than parked as cash, including through their commitment to maintain at least their 28.4% stake in the newly listed Idorsia.

Current Idorsia holdings

As of the most recent shareholder disclosures, Jean-Paul Clozel directly holds approximately 42,088,773 Idorsia shares, representing roughly 16.73% of outstanding shares (per ADVFN insider data dated October 2025 and corroborated by Simply Wall St ownership data). Note that this is his individual holding; the combined Clozel family stake, which at IPO was 28.4%, has evolved as Idorsia issued new shares for financings. Idorsia's 2024 Annual Report also discloses that Jean-Paul Clozel held 11,031,347 conversion rights from convertible bonds, and Martine Clozel held 3,952,124, as of December 31, 2024. These conversion rights represent additional potential equity that a simple share-count approach would miss entirely. Idorsia's 2025 Annual Report, published February 26, 2026, is the most recent primary source for year-end holdings and should be the first document anyone checks for an updated figure.

Idorsia has faced serious financial pressure, including restructuring, asset sales, and share issuances that diluted earlier holders. Its market capitalization has contracted substantially from its peak. At a share price in the CHF 2 to CHF 5 range (which has been roughly characteristic of Idorsia during 2024 to 2026 given the company's difficulties), 42 million shares implies a mark-to-market value of approximately CHF 84 million to CHF 210 million for the direct share stake alone. Adding in the conversion rights and any separate cash or other assets, the CHF 150 million to CHF 400 million range is a reasonable working estimate, with the lower end reflecting a depressed share price scenario and the upper end reflecting a partial recovery plus conversion-rights value.

It is also worth noting that Wikipedia references a private loan of CHF 75 million that Jean-Paul Clozel provided to Idorsia. If accurate (and it should be verified against primary Idorsia filings before being relied upon), this represents both a financial asset (a loan receivable) and a signal of personal liquidity, though it also represents concentration risk: his personal balance sheet is deeply tied to Idorsia's health.

Where his wealth likely comes from

Clozel's wealth story has three overlapping chapters.

• Actelion equity proceeds: As a co-founder with a multi-decade ownership stake, he and Martine received a large cash payout when J&J closed the $30 billion acquisition in June 2017. Even after reinvestment into Idorsia and personal expenses, this represents the foundation of his wealth.
• Idorsia equity: The Clozels retained a 28.4% combined stake in Idorsia at IPO and have remained major shareholders. As of 2025, Jean-Paul's direct stake is approximately 16.73% based on disclosed filings. This is the most volatile component of his current wealth, moving dollar-for-dollar with Idorsia's share price.
• Convertible bond instruments: Both Jean-Paul and Martine hold conversion rights from Idorsia convertible bonds. These add optionality to their equity position and are separately disclosed in Idorsia's annual financial reports.
• The CHF 75 million private loan to Idorsia: If confirmed in primary filings, this represents another financial asset on his personal balance sheet, though one whose recoverability depends on Idorsia's financial performance.
• Salary and executive compensation: Annual compensation as CEO and Chairman would add modest incremental wealth relative to the equity stakes, and should not be confused with net worth itself.

How this site estimates net worth

For figures like Jean-Paul Clozel, where the dominant asset is a disclosed equity stake in a listed company, the methodology is relatively grounded compared to estimating private wealth for someone with no public filings. Here is how the estimate is built.

1. Start with the most recent primary source: Idorsia's Annual Report significant shareholder or major shareholders table, cross-referenced with SIX Exchange threshold disclosures. The 2025 Annual Report (published February 26, 2026) is the freshest available anchor.
2. Identify the share count: 42,088,773 shares directly attributed to Jean-Paul Clozel per disclosed 2025 data.
3. Apply the contemporaneous share price: Use the Idorsia share price on the SIX Swiss Exchange at or near the reporting date. Multiply shares by price to get a mark-to-market equity value.
4. Add disclosed equity instruments: Layer in the conversion rights from convertible bonds (11 million-plus for Jean-Paul as of end-2024) using a conservative in-the-money assumption or a range.
5. Add non-equity signals: The CHF 75 million private loan, if verified in primary filings, is added at face value with a note about recovery risk.
6. Apply a liquidity discount: A large insider block in a mid-cap biotech cannot be sold at market price overnight. A 15 to 25 percent discount is applied to the equity value to reflect this.
7. Set a range, not a point estimate: The final output is a range reflecting share price sensitivity, conversion-rights valuation uncertainty, and undisclosed personal assets.
8. Flag what is not known: Personal real estate, private investment portfolios, cash from Actelion proceeds not reinvested, and any liabilities are not disclosed and are not included in the estimate.

This approach means the estimate is only as current as the latest share price and disclosed holdings. It is not a static number, it is a model that needs to be refreshed whenever Idorsia's share price moves significantly or new shareholder disclosures are filed.

What could move his net worth significantly

Because most of Clozel's estimated wealth is tied to Idorsia's equity, the list of catalysts is essentially Idorsia's corporate story.

It is also worth noting that leadership transitions matter. Clozel's shift from CEO to Chairman, and then back to interim CEO during transitions, affects how tightly his personal brand and financial fate are tied to the company's trajectory. The more active he is in the company's operations, the more signal value his actions (such as buying or not selling shares) carry for outside observers.

Common mistakes and how to verify the claim yourself

Mistakes to avoid

• Confusing compensation with net worth: Idorsia's annual compensation disclosures show what Clozel earned as CEO or Chairman in a given year. That is salary plus equity grants, not total wealth. The number will be a fraction of his actual net worth.
• Trusting 'instant net worth' websites without checking their sources: Many sites publish figures like '$2 billion' or '$500 million' with no methodology. For a figure like Clozel, these are almost always extrapolated from the Actelion deal size without accounting for reinvestment, dilution, or Idorsia's current valuation.
• Using outdated ownership percentages: The Clozels' original 28.4% combined Idorsia stake has been diluted through subsequent share issuances. The current disclosed figure for Jean-Paul individually is approximately 16.73%, and the combined family stake should be checked in the latest annual report.
• Ignoring currency: Idorsia trades in CHF on SIX. Converting to USD or EUR without noting the exchange rate and timing introduces additional error.
• Ignoring conversion rights: Any estimate that only counts direct shares misses the 11-plus million conversion rights Jean-Paul holds, which represent additional equity upside.
• Treating the Actelion $30B deal as entirely Clozel's: The $30 billion was the total acquisition price for all shareholders. The Clozels' approximately 5% stake (per 2015 data) would correspond to roughly $1.5 billion in gross deal value, not $30 billion personally.

How to verify quickly

1. Go to Idorsia's investor relations page and download the most recent Annual Report (the 2025 report was published February 26, 2026). Find the 'Significant Shareholders' or 'Major Shareholders' table for the end-of-year share count.
2. Check SIX Exchange's disclosure database for threshold notifications filed by Jean-Paul or Martine Clozel. Any time their combined or individual stake crosses a 3%, 5%, 10%, or higher threshold, a public notification must be filed within four trading days under Swiss law.
3. Look up the current Idorsia share price on SIX Swiss Exchange (ticker: IDIA) and multiply by the disclosed share count to get a real-time mark-to-market equity value.
4. Check the Idorsia Annual Report finance section for convertible bond conversion rights held by insiders (disclosed in the notes to financial statements) to add that layer to the estimate.
5. Cross-reference with Simply Wall St or ADVFN for an independent cross-check of the share count, but always treat those as secondary to Idorsia's own filings.
6. Discount the result by 15 to 25 percent for liquidity, and express it as a range rather than a single number.

If you are doing research that compares Clozel's wealth to other prominent figures in Swiss or French business, it is worth noting that Swiss disclosure rules make insider equity stakes more traceable than in many other jurisdictions, but personal wealth beyond listed equity remains opaque. Other notable individuals in the French and international business world who are covered on this site offer useful comparison points for understanding how founder wealth from major pharmaceutical or corporate deals typically maps to ongoing net worth estimates.

The bottom line: Jean-Paul Clozel is a genuinely wealthy individual whose financial story is rooted in building and selling one of Europe's most successful biotechs. If you are also comparing how founder wealth is framed in popular searches, see jean claude net worth as a related example of how these estimates can be presented differently online. If you are specifically looking for Jean-Claude Blanc net worth, you will want to compare how his disclosed holdings and sources of wealth line up with similarly sourced estimates Jean-Paul Clozel. The credible range as of May 2026 is CHF 150 million to CHF 400 million, dominated by his Idorsia equity stake and related instruments, with significant uncertainty at both ends depending on Idorsia's share price and financial trajectory. That range could compress upward quickly on a positive clinical or deal catalyst, or compress downward if Idorsia's financial situation deteriorates further. If you are also looking up jean louis trintignant net worth, remember that celebrity net-worth figures can move just as fast when new deals or verified disclosures appear. Treat any figure outside this range with skepticism unless it comes with a transparent methodology and primary source documentation. If you are specifically trying to pin down Jean-Claude Gandur net worth, the same public-signal approach can help you separate confirmed ownership from speculation.